Men with prostate cancer treated with either LHRH agonist injections, oral LHRH antagonist, or tE2 patches have similar rates of castration [3, 4], a surrogate marker of efficacy of ADT [5]. This evidence concerns the gene GNRH1 and prostate carcinoma.